Q3 2010

Filed Nov 22, 2010 · 10-Q · 53 days after period end · 0001424884-10-000150

Q3 2010 · 10-Q

Revenue—

Net Income

-$1.01M

no prior Q3 2009 on file

EPS Diluted

-$0.03

no prior Q3 2009 on file

Operating Income-$1,233,858—

Operating Cash Flowderived-$254,821—

Same quarter

no prior Q3 2009 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Sep 30, 2010 · filed Nov 22, 2010 · 53 d after period end

Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR